Pfizer, Inc. Stock Deutsche Boerse AG

Equities

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Tradegate 11:33:14 2024-05-03 EDT 5-day change 1st Jan Change
25.63 EUR -0.78% Intraday chart for Pfizer, Inc. +7.79% -1.67%

Financials

Sales 2024 * 60.13B 55.83B 82.29B Sales 2025 * 62.49B 58.02B 85.52B Capitalization 157B 146B 215B
Net income 2024 * 7.91B 7.34B 10.82B Net income 2025 * 10.19B 9.46B 13.95B EV / Sales 2024 * 3.5 x
Net Debt 2024 * 53.77B 49.92B 73.58B Net Debt 2025 * 42.59B 39.54B 58.28B EV / Sales 2025 * 3.19 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
13.7 x
Employees 88,000
Yield 2024 *
6.11%
Yield 2025 *
6.22%
Free-Float 59.09%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.78%
1 week+7.79%
Current month+6.98%
1 month+1.70%
3 months+3.28%
6 months-12.11%
Current year-1.67%
More quotes
1 week
23.80
Extreme 23.795
26.06
1 month
23.57
Extreme 23.57
26.06
Current year
23.57
Extreme 23.57
27.65
1 year
23.57
Extreme 23.57
37.45
3 years
23.57
Extreme 23.57
54.50
5 years
23.57
Extreme 23.57
54.50
10 years
20.74
Extreme 20.735
54.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 92-12-31
Director of Finance/CFO 59 22-05-01
Chief Tech/Sci/R&D Officer - 19-06-30
Members of the board TitleAgeSince
Director/Board Member 66 20-03-31
Director/Board Member 64 17-02-22
Director/Board Member 60 13-09-26
More insiders
Date Price Change Volume
24-05-03 25.66 -0.64% 5 626
24-05-02 25.83 +7.67% 11,652
24-04-30 23.99 +0.38% 3,894
24-04-29 23.9 +0.38% 11,246
24-04-26 23.81 +0.53% 6,979

Delayed Quote Deutsche Boerse AG, May 03, 2024 at 10:36 am

More quotes
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
27.7 USD
Average target price
31.89 USD
Spread / Average Target
+15.14%
Consensus